PHAGEBANK SUSCEPTIBILITY TEST
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

PHAGEBANK SUSCEPTIBILITY TEST Trademark

Serial Number: 97074042

PHAGEBANK SUSCEPTIBILITY TEST is a trademark filed by Adaptive Phage Therapeutics, Inc. on October 14, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Adaptive Phage Therapeutics, Inc. (25 trademarks)

Gaithersburg, MD 20878

Entity Type: 03

Trademark Details

Filing Date

October 14, 2021

Registration Date

Not Registered

Goods & Services

providing medical diagnostic assays and diagnostic and prognostic testing for treatment purposes of bacteria infections, and the analysis, evaluation, and reporting of those test results to help healthcare professionals determine a patient's clinical diagnosis, the effectiveness of patient treatments, and to revise future treatments accordingly; medical services; consulting services in the field of medical diagnostic and prognostic testing; medical analysis services for diagnostic and prognostic testing and treatment purposes; providing medical diagnostic and prognostic testing services; medical analysis services relating to the diagnosis and treatment of person; microbiological laboratory testing of bacteria for diagnostic and medical purposes, and technical consultation thereto; medical testing and diagnostic services for diagnostic or treatment purposes, in particular performing tests using diagnostic assays

diagnostic kits comprised of medical diagnostic reagents for testing for bacteria sensitivity

diagnostic reagents for clinical and medical laboratory use; diagnostic kits comprised of reagents for testing for bacteria sensitivity

providing medical diagnostic assays and diagnostic and prognostic testing for medical research purposes of bacterial infections, and the analysis, evaluation, and reporting of those test results to help healthcare professionals for research purposes; development of new technology for others in the field of biotechnology; laboratory research in the field of genomic sequencing; research and development in the pharmaceutical and biotechnology fields; research, development, engineering and testing services in the fields of bacteria and viruses; laboratory research in the field of infectious diseases; medical and scientific research in the field of immunotherapy; medical laboratory services; microbiological laboratory testing of bacteria for research purposes, and technical consultation thereto; scientific and medical research, in particular design and development of diagnostic assays

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Feb 7, 2023 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Feb 7, 2023 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Feb 7, 2023 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 22, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jul 22, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jul 22, 2022 CNRT
ASSIGNED TO EXAMINER
Jul 20, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 3, 2021 NWOS
NEW APPLICATION ENTERED
Oct 18, 2021 NWAP